Ganciclovir ophthalmic gel (Laboratoires Thea)

更昔洛韦眼用凝胶 (Laboratoires Thea)

Report date: 2025/06/17 14:18:11

Base Information

Drug NameGanciclovir ophthalmic gel (Laboratoires Thea)
Drug Alias Name0.15% Ganciclovir ophthalmic gelVirganZirganST-605ROH-101
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman herpesvirus 1 DNA polymerase inhibitors
TargetsHuman herpesvirus 1 DNA polymerase
Therapy Area/IndicationsCytomegalovirus corneal endotheliitisKeratitis, HerpeticEye Infections, Viral
Global Approved IndicationsKeratitis, Herpetic
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date1998/08/25
Country/TerritoryUnited StatesUnited KingdomSouth Korea +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesLaboratoires Théa, France
China Registration ClassN/A

Develop Information

Active CompaniesSamil Pharmaceutical Co LtdLaboratoires Théa, FranceBausch And Lomb Inc
Inactive CompaniesN/A
Active IndicationsCytomegalovirus corneal endotheliitisKeratitis, HerpeticEye Infections, Viral
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A